Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: The DRIVE UK Study

Eye

Volumn 26, Issue 4, 2012, Pages 510-516

  Gupta, B ^a   Sivaprasad, S ^a   Wong, R ^b   Laidlaw, A ^b   Jackson, T L ^a   McHugh, D ^a   Williamson, T H ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

non clearing vitreous haemorrhage; pars plana vitrectomy; proliferative diabetic retinopathy; tractional retinal detachment

Indexed keywords

BEVACIZUMAB; INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PREVALENCE; RETINA DETACHMENT; RETINA MACULOPATHY; TREATMENT INDICATION; UNITED KINGDOM; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 84859764321     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.321     Document Type: Article

References (20)

1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82(11): 844-851.
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782-787.
3. Fine SL, Patz A. Ten years after the Diabetic Retinopathy Study. Ophthalmology 1987; 94(7): 739-740.
4. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 1985; 103(11): 1644-1652.
5. Williams DF, Williams GA, Hartz A, Mieler WF, Abrams GW, Aaberg TM. Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique. Ophthalmology 1989; 96(6): 752-758.
6. Arevalo JF, Wu L, Sanchez JG, Maia M, Saravia MJ, Fernandez CF et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye (Lond) 2009; 23(1): 117-123.
7. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina 2010; 30(7): 1046-1050.
8. Yorston D, Wickham L, Benson S, Bunce C, Sheard R, Charteris D. Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 365-368.
9. Mason III JO, Colagross CT, Haleman T, Fuller JJ, White MF, Feist RM et al. Visual outcome and risk factors for light perception and no light perception vision after vitrectomy for diabetic retinopathy. Am J Ophthalmol 2005; 140(2): 231-235.
10. Smiddy WE, Feuer W, Irvine WD, Flynn Jr HW, Blankenship GW. Vitrectomy for complications of proliferative diabetic retinopathy. Functional outcomes. Ophthalmology 1995; 102(11): 1688-1695.
11. Yorston D, Wickham L, Benson S, Bunce C, Sheard R, Charteris D. Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92(3): 365-368.
12. Thompson JT, de BS, Michels RG, Rice TA, Glaser BM. Results of vitrectomy for proliferative diabetic retinopathy. Ophthalmology 1986; 93(12): 1571-1574.
13. DRVS. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trialFDiabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988; 95(10): 1307-1320.
14. Rizzo S, Genovesi-Ebert F, di BE, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008; 246(6): 837-842.
15. da RL, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009; 93(5): 688-691.
16. Steel DH, Connor A, Habib MS, Owen R. Entry site treatment to prevent late recurrent postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol 2010; 94(9): 1219-1225.
17. Bandello F, Battaglia PM, Lanzetta P, Loewenstein A, Massin P, Menchini F et al. Diabetic macular edema. Dev Ophthalmol 2010; 47: 73-110.
18. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008; 28(8): 1053-1060.
19. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116(6): 1142-1150.
20. Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand 2001; 79(5): 435-402.